Kura Oncology Q3 net loss $35.5M; $150M financing; ziftomenib data at ASH

Kura Oncology, Inc.

2022-Q3 EPS reported -$1.54

Q3 net loss $35.5M vs $33.4M YoY; R&D expense $25.0M, G&A $11.6M.
Cash, equivalents & short-term investments $427.8M pro forma $462.8M after $25M BMS equity and $10M Hercules draw.
$125M Hercules term loan: $10M drawn immediately, up to $115M additional upon milestones; runway into 2026.
Updated ziftomenib Phase 1 data from KOMET-001 accepted for oral presentation at ASH Dec 10, 2022.
AIM-HN registration trial of tipifarnib in HRAS mutant HNSCC closed to enrollment; KURRENT-LUNG trial initiated.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kura Oncology, Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 3, 2022, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2022 and providing a corporate update.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Kura Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-021564

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.